Source: European Medicines Agency (EU) Revision Year: 2022 Publisher: Instituto Grifols, S.A., Can Guasc, 2 Parets del Vallès, E-08150 Barcelona Spain
VeraSeal must not be applied intravascularly.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
VeraSeal must not be used for the treatment of severe or brisk arterial bleeding.
For epilesional use only. Do not apply intravascularly.
Life threatening thromboembolic complications may occur if the preparation is unintentionally applied intravascularly (see section 4.8).
VeraSeal spray application should only be used if it is possible to accurately judge the spray distance, especially during laparoscopy. Spray distance from tissue should be within the range recommended by the marketing authorisation holder of VeraSeal (see section 6.6).
When using accessory tips, the instructions for use of the tips should be followed.
Before administration of VeraSeal, care must be taken that the parts of the body outside the desired application area are sufficiently protected (covered) to prevent tissue adhesion at undesired sites.
VeraSeal should be applied as a thin layer. Excessive clot thickness may negatively interfere with the product’s efficacy and the wound healing process.
Adequate data are not available to support the use of this product in tissue gluing, neurosurgery, application through a flexible endoscope for treatment of bleeding or in gastrointestinal anastomoses.
As with any protein product, allergic type hypersensitivity reactions are possible. Signs of hypersensitivity reactions include hives, generalised urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. If these symptoms occur, the administration must be discontinued immediately. In case of shock, standard medical treatment for shock should be implemented.
Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation /removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.
The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A virus. The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection may be serious for pregnant women (foetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g. haemolytic anaemia).
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
No formal interaction studies have been performed. Similar to comparable products or thrombin solutions, the product may be denatured after exposure to solutions containing alcohol, iodine or heavy metals (e.g. antiseptic solutions). Such substances should be removed to the greatest possible extent before applying the product.
The safety of fibrin sealant/haemostatic products for use in human pregnancy or breast-feeding has not been established in controlled clinical trials. Experimental animal studies are insufficient to assess the safety with respect to reproduction, development of the embryo or foetus, the course of gestation and peri- and post-natal development. Therefore, the product should be administered to pregnant and breast-feeding women only if clearly needed.
Fertility studies have not been conducted.
Not relevant.
Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the application site, bronchospasm, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) may occur in rare cases in patients treated with fibrin sealant/haemostatic products. In isolated cases, these reactions have progressed to severe anaphylaxis. Such reactions may especially be seen, if the preparation is applied repeatedly, or administered to patients known to be hypersensitive to constituents of the product.
Antibodies against components of fibrin sealant/haemostatic products may occur rarely.
Inadvertent intravascular injection could lead to thromboembolic event and disseminated intravascular coagulation (DIC), and there is also a risk of anaphylactic reaction (see section 4.4).
For safety information with respect to transmissible agents, see section 4.4.
The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level).
Frequencies have been evaluated according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing of seriousness.
Frequency of Adverse Reactions (ADRs) in clinical studies with VeraSeal:
MedDRA System Organ Class (SOC) | Adverse reaction | Frequency |
---|---|---|
Infections and infestations | Abdominal abscess, cellulitis, liver abscess, peritonitis, postoperative wound infection, wound infection incision site infection, post procedural infection. | Uncommon |
Neoplasms benign, malignant and unspecified (including cysts and polyps) | Plasma cell myeloma | Uncommon |
Blood and lymphatic system disorders | Anaemia, haemorrhagic anaemia, leukocytosis, leukopenia | Uncommon |
Immune system disorders | Hypersensitivity* | Unknown |
Metabolism and nutrition disorders | Hyperglycaemia, hyperkalaemia, hypocalcaemia, hypoglycaemia, hypokalaemia, hypomagnesemia, hyponatraemia, hypoproteinaemia | Uncommon |
Psychiatric disorders | Anxiety, insomnia | Uncommon |
Nervous system disorders | Headache, somnolence | Uncommon |
Eye disorders | Conjunctival irritation | Uncommon |
Cardiac disorders | Atrial fibrillation, ventricular tachycardia | Uncommon |
Vascular disorders | Deep vein thrombosis, hypertension, hypotension | Uncommon |
Respiratory, thoracic and mediastinal disorders | Pulmonary embolism, dyspnoea, hypoxia, pleural effusion, pleurisy, pulmonary oedema, rhonchi, wheezing | Uncommon |
Gastrointestinal disorders | Nausea | Common |
Constipation, flatulence, ileus, retroperitoneal haematoma, vomiting | Uncommon | |
Skin and subcutaneous tissue disorders | Pruritus | Common |
Ecchymosis, erythema | Uncommon | |
Musculoskeletal and connective tissue disorders | Back pain, pain in extremity | Uncommon |
Renal and urinary disorders | Bladder spasm, dysuria, urinary retention | Uncommon |
General disorders and administration site conditions | Chills, hyperthermia, oedema peripheral, pain, pyrexia, vessel puncture site haematoma | Uncommon |
Investigations | Parvovirus B19 test positive, activated partial thromboplastin time prolonged, alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increase, blood glucose increase, international normalised ratio increased, prothrombin time prolonged, transaminases increased, urine output decreased | Uncommon |
Drug specific antibody present* | Unknown | |
Injury, poisoning and procedural complications | Procedural pain | Common |
Abdominal wound dehiscence, post procedural bile leak, contusion, incision site erythema, incision site pain, post procedural haemorrhage, procedural hypotension, vascular graft complication, vascular graft thrombosis, wound secretion | Uncommon |
* All these reactions are class effect. None were reported in clinical trials; thus it is not possible to establish frequencies.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
This medicinal product must not be mixed with other medicinal products.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.